Prediabetes and risk of all-cause and cause-specific mortality: a prospective study of 114,062 adults in Mexico City.
Fermín-Martínez CA. et al, (2025), J Clin Endocrinol Metab
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Type 2 diabetes and cause-specific mortality in Mexico City: a Mendelian randomisation analysis
EMBERSON J. et al, (2025), The Lancet Regional Health - Americas
Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.
Hammami I. et al, (2025), Heart
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.
Mitchell J. et al, (2025), Nat Commun, 16
Polygenic prediction of coronary artery disease among 130,000 Mexican adults
EMBERSON J. et al, (2025)
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
HAYNES R. et al, (2025), EClinicalMedicine
Author Correction: A deep catalogue of protein-coding variation in 983,578 individuals.
Sun KY. et al, (2025), Nature, 637
Cognitive impairment at older ages among 8000 men and women living in Mexico City: a cross-sectional analyses of a prospective study.
González-Carballo C. et al, (2024), BMC Public Health, 24
Abstract 4113475: Association of Age at Diabetes Diagnosis and All-cause and Cardiovascular Mortality among 600,000 US Adults
Thomson B. et al, (2024), Circulation, 150, a4113475 - a4113475
Alcohol and mortality in Mexico: prospective study of 150 000 adults.
Trichia E. et al, (2024), Lancet Public Health, 9, e907 - e915
Blood Pressure, eGFR, and Kidney Mortality in Mexico: A Prospective Study of 150,000 Adults
Zhu D. et al, (2024), Journal of the American Society of Nephrology, 35
Design, recruitment and baseline characteristics of the LENS trial.
LENS Collaborative Group None., (2024), Diabet Med, 41
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Associations of fruit intake with adiposity and cardiometabolic biomarkers in UK Biobank.
Trichia E. et al, (2024), BMC Public Health, 24